GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts


“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable fragment (scFv) display and molecular genomics. “The challenge,” Johnson explains, “is keeping the heavy and light chains of the antibodies intact at a single-cell level to maintain the functionality of the antibodies.”

Read the full article.